Diego A. Díaz García/X
Mar 26, 2025, 17:54
Diego A. Díaz García: Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutant advanced NSCLC whose DP on 1L osimertinib
Diego A. Díaz García, Medical Oncologist /CEO/Founder at CánCare – High Specialty in Oncology, shared on X:
“ORCHARD: Osimertinib plus datopotamab deruxtecan in patients with EGFRm aNSCLC whose DP on 1L osimertinib.
ORR: Osi + Dato-Dxd 4mg (ODd4) 43%, Osi + Dato-Dxd 6mg (ODd6) 36%.
Median PFS 9.5m and 11.7m , 12m PFS 21% % 39%.
- TROPION-Lung14 Dato-Dxd + osimertinib as 1L tx for adv nsqNSCLC EGFRmut
- TROPION-Lung15 Dato-Dxd +- osimertinib for adv EGFRm nsqNSCLC after PD on osimertinib.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 1, 2025, 04:49
Apr 1, 2025, 04:37
Apr 1, 2025, 03:30